Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
Zeitschrift für Gastroenterologie | September 4, 2025 | Volume: 63 | Issue: No issue available | Pages: No page available
10.1055/s-0045-1810728